<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="274">
  <stage>Registered</stage>
  <submitdate>11/10/2001</submitdate>
  <approvaldate>11/10/2001</approvaldate>
  <nctid>NCT00025324</nctid>
  <trial_identification>
    <studytitle>Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors</studytitle>
    <scientifictitle>Clinical Correlative Studies In Primary Central Nervous System Germ Cell Tumors: The Third International CNS Germ Cell Tumor Study Group Protocol</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CHLA-NYU-0007H</secondaryid>
    <secondaryid>CDR0000068950</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain and Central Nervous System Tumors</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Testicular</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - filgrastim
Treatment: drugs - carboplatin
Treatment: drugs - cyclophosphamide
Treatment: drugs - etoposide
Treatment: drugs - thiotepa
Treatment: surgery - autologous bone marrow transplantation
Treatment: surgery - bone marrow ablation with stem cell support
Treatment: surgery - conventional surgery
Treatment: surgery - peripheral blood stem cell transplantation
Treatment: other - radiation therapy

Other interventions: filgrastim


Treatment: drugs: carboplatin


Treatment: drugs: cyclophosphamide


Treatment: drugs: etoposide


Treatment: drugs: thiotepa


Treatment: surgery: autologous bone marrow transplantation


Treatment: surgery: bone marrow ablation with stem cell support


Treatment: surgery: conventional surgery


Treatment: surgery: peripheral blood stem cell transplantation


Treatment: other: radiation therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed newly diagnosed primary CNS germ cell tumor OR

          -  Serum or cerebrospinal fluid (CSF) elevation of alpha-fetoprotein (AFP) or beta-human
             chorionic gonadotropin (beta-HCG) greater than 50 ng/mL

          -  Low-risk disease:

               -  Histologically proven pure germinoma

               -  Localized, nonmetastatic disease

               -  Normal CSF

               -  Normal serum tumor markers

          -  Intermediate-risk disease:

               -  Histologically proven germinoma

               -  Beta-HCG-positive syncytiotrophoblastic giant cell component AND/OR

               -  CSF elevation of beta-HCG to less than 50 ng/mL

          -  High-risk disease:

               -  Histologically proven choriocarcinoma, endodermal sinus tumor, or embryonal
                  carcinoma

               -  Elevated serum and/or CSF AFP OR

               -  Elevated serum beta-HCG OR

               -  Elevated CSF beta-HCG greater than 50 ng/mL OR

               -  Disseminated disease by MRI and/or CSF cytology

        PATIENT CHARACTERISTICS:

        Age:

          -  Any age

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin less than 2.0 mg/dL

          -  Indirect hyperbilirubinemia due to Gilbert's syndrome is allowed

          -  AST and ALT less than 5 times upper limit of normal

        Renal:

          -  Creatinine clearance greater than 60 mL/min

        Cardiovascular:

          -  Cardiac function normal by echocardiogram

          -  No myocardial infarction or ischemia in patients over 30 years

          -  Fractional shortening greater than 30%

        Other:

          -  No unacceptable morbidity of organ systems outside the CNS

          -  Not pregnant

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  No concurrent corticosteroids administered solely for antiemesis during study
             chemotherapy

        Radiotherapy:

          -  No prior cranial radiotherapy

        Surgery:

          -  Not specified</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Hospital Los Angeles</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
      Radiation therapy uses high-energy x-rays to damage tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of chemotherapy, surgery, radiation
      therapy, and bone marrow or peripheral stem cell transplantation in treating patients who
      have primary CNS germ cell tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00025324</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jonathan L. Finlay, MB, ChB</name>
      <address>Children's Hospital Los Angeles</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>